ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Impact of Everolimus on Secondary Nonmelanoma Skin Cancer Prevention in Solid Organ Transplant Recipients

B. Clark1, D. D. Ramirez1, A. Carlson1, B. Sirandas1, C. Truax1, L. Smith1, I. Hall2

1Solid Organ Transplant, University of Utah Health, Salt Lake City, UT, 2Nephrology and Hypertension, University of Utah Health, Salt Lake City, UT

Meeting: 2019 American Transplant Congress

Abstract number: D331

Keywords: Post-transplant malignancy, Recurrence

Session Information

Date: Tuesday, June 4, 2019

Session Name: Poster Session D: PTLD/Malignancies: All Topics

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

Related Abstracts
  • Association between De Novo Post-Transplant Nonmelanoma Skin Cancer and Solid Tumor after Solid Organ Transplantation – An Analysis of OPTN/UNOS Data
  • Nonmelanoma Skin Cancer Rates Are Not Affected by Chronic HIV(+) or HCV(+) Infection in Organ Transplant Recipients.

*Purpose: Over half of solid organ transplant recipients (SOTR) develop nonmelanoma skin cancers (NMSC) and up to 80% experience recurrence. Many immunosuppressive drugs are known to have direct oncogenic effects. Current guidelines recommend mTOR inhibitors in patients with NMSC due to their antineoplastic properties. Studies have shown that transitioning SOTR from a CNI to sirolimus reduces recurrence of NMSC. However, this benefit has not been formally associated with everolimus (EVR). This study aims to evaluate the impact of everolimus (EVR) on recurrence of nonmelanoma skin cancer (NMSC) in solid organ transplant recipients (SOTR).

*Methods: This was a retrospective cohort study performed at an academic medical center. Included patients were adult SOTR with a history of posttransplant NMSC. Patients were excluded if they had a history of any cancer pretransplant, nonskin cancer or melanoma skin cancer posttransplant, or if the immunosuppressive regimen contained sirolimus or belatacept. Recurrence of NMSC within 3 years of initial diagnosis was compared between patients who received EVR following diagnosis (n=11) and a control group of patients who were kept on regimens not containing an mTOR inhibitor (n=28). Secondary outcomes included impact of EVR on time to recurrence of NMSC and EVR discontinuations due to adverse effects.

*Results: Baseline patient characteristics were similar between groups. Eight patients (72%) in the EVR group and 18 patients (64%) in the control group experienced recurrence of NMSC within 3 years (p=0.72). Eight patients (72%) in the EVR group had no recurrence after initiation of EVR (p=0.13). Refer to Table 1. The median time from NMSC diagnosis to EVR initiation was 393 days. The median time to first recurrence was 299 days in the EVR group and 432 days in the control group. Four patients discontinued EVR due to adverse effects (p=0.16).

*Conclusions: Transitioning to an EVR containing regimen was not associated with a reduction in recurrence of NMSC in this cohort. A limitation of this observation is that the median time to EVR initiation after NMSC diagnosis was greater than the median time to first recurrence. While not statistically significant, 2 patients experienced potential serious adverse effects and 2 patients experienced minor adverse effects of EVR necessitating discontinuation. Limitations of this study include the observational study design and the small number of patients switched to EVR.

NMSC Recurrences
Total recurrence within 3 years of initial diagnosisNo recurrenceRecurrence prior to EVRRecurrence after EVR
EG8353
CG1810––
  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Clark B, Ramirez DD, Carlson A, Sirandas B, Truax C, Smith L, Hall I. Impact of Everolimus on Secondary Nonmelanoma Skin Cancer Prevention in Solid Organ Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/impact-of-everolimus-on-secondary-nonmelanoma-skin-cancer-prevention-in-solid-organ-transplant-recipients/. Accessed December 4, 2019.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population
  • Penis Transplantation: First U.S. Experience.
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2019 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

wiley-new-logo

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.